Medtronic (BSP:MDTC34) Total Equity: R$252,057 Mil (As of Apr. 2026)


BSP:MDTC34 Medtronic PLC BSP:MDTC34
67 GF Score
Price R$212.52
GF Value R$246.75
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Medtronic Total Equity?

Medtronic BSP:MDTC34 +2.47% 67 Total Equity is R$252,057 Mil as of Apr. 2026. GuruFocus rates BSP:MDTC34 with a GF Score™ of 67/100 and a GF Value™ of R$246.75 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Medtronic's total equity for the quarter that ended in Apr. 2026 was R$252,057 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Medtronic Total Equity Historical Data

* Premium members only.

The historical data trend for Medtronic's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medtronic Total Equity Chart

Medtronic Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 250,677.29 259,435.80 258,654.60 279,426.37 252,057.44

Medtronic Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 279,426.37 266,329.52 263,007.00 262,293.39 252,057.44
BSP:MDTC34
67GF Score
Medtronic PLC BSP:MDTC34
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medtronic Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Medtronic's Total Equity for the fiscal year that ended in Apr. 2026 is calculated as

Total Equity=Total Assets(Q: Apr. 2026 )-Total Liabilities(Q: Apr. 2026 )
=468293.649-216236.208
=252,057

Medtronic's Total Equity for the quarter that ended in Apr. 2026 is calculated as

Total Equity=Total Assets(Q: Apr. 2026 )-Total Liabilities(Q: Apr. 2026 )
=468293.649-216236.208
=252,057

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of R$252,057 Mil mean?
Medtronic (BSP:MDTC34) has a Total Equity of R$252,057 Mil as of Apr. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Medtronic and its competitors.
Is Medtronic's Total Equity too high?
Medtronic's current Total Equity is R$252,057 Mil. Overall, Medtronic has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medtronic's Total Equity compare to SYK and BSX?
Medtronic's Total Equity of R$252,057 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Medtronic and its competitors. Medtronic's current Total Equity is R$252,057 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtronic stock overvalued right now?
Based on GuruFocus' analysis, Medtronic (BSP:MDTC34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$246.75, compared to a current price of R$212.52 — trading 13.9% below its estimated fair value. The current Total Equity is R$252,057 Mil. Medtronic's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Medtronic (BSP:MDTC34), the current Total Equity is R$252,057 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medtronic (BSP:MDTC34) Overvalued in 2026?

Based on GuruFocus' analysis, Medtronic stock appears to be undervalued. The current stock price of R$212.52 is trading 13.9% below its estimated GF Value™ of R$246.75. GuruFocus considers Medtronic to be Modestly Undervalued.

Key valuation signals for BSP:MDTC34:

  • Total Equity: R$252,057 Mil
  • GF Value™: R$246.75 vs. price of R$212.52 (13.9% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the BSP:MDTC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medtronic Business Description

Address Parkmore Business Park West, Building Two, Galway, IRL
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
67GF Score

Get the complete analysis for BSP:MDTC34

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$212.52
Price
R$246.75
GF Value